GEV vs PFE: Which Is the Better Buy?
Side-by-side comparison of GE Vernova Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-25.
GE Vernova Inc. · Industrials
$1,014.75
-16.2% upside to fair value
Med Conviction
Grade C+
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GEV |
PFE |
| Current Price |
$1,014.75 |
$25.22 |
| Fair Value Estimate |
$850.00 |
$25.92 |
| Upside to Fair Value |
-16.2%
|
+2.8%
|
| Market Cap |
$270.3B |
$143.7B |
| Forward P/E |
34.3x
|
19.2x
|
| EV / EBITDA |
25.6x
|
12.3x
|
| Price / Sales |
6.6x
|
2.3x
|
| Price / FCF |
22.0x
|
15.2x
|
| Revenue Growth YoY |
+15.0%
|
+5.4%
|
| Gross Margin |
21.3%
|
69.3%
|
| Operating Margin |
5.9%
|
23.4%
|
| Return on Equity |
30.0%
|
8.4%
|
| Dividend Yield |
0.17% |
0% |
| FCF Yield |
4.5%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
GE Vernova is the premier pure-play on the electricity side of the AI infrastructure supercycle. Its Power (heavy-duty gas turbines) and Electrification (grid equipment) segments are structurally supply-constrained, backed by a record $176B backlog that management says is 'mostly sold out through 2030.' The company raised FY2026 guidance for a second straight quarter to $45.5-46.5B revenue and $1…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
GEV |
PFE |
| Zone Low |
$640.00 |
$19.44 |
| Zone High |
$723.00 |
$22.03 |
| In Buy Zone? |
No
|
No
|